Palvella Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Palvella Therapeutics, Inc. (PVLA) reported Net Income (Loss) Available to Common Stockholders, Basic of -$11.35 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2025-11-12
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$11.35M.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-06-30 was -$9.47M.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-03-31 was -$8.19M.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2024-12-31 was -$3.37M.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$17.43M, a 197.32% decline from fiscal 2023.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was $17.91M.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$37.23M.
- Palvella Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$28.30M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2025-09-30 | -$11.35M 10-Q · filed 2025-11-12 | -$20.82M derived: sum of 2 quarters · filed 2025-11-12 | -$29.00M 10-Q · filed 2025-11-12 | -$32.37M derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-06-30 | -$9.47M 10-Q · filed 2025-08-14 | -$17.66M 10-Q · filed 2025-08-14 | -$21.02M derived: sum of 3 quarters · filed 2025-08-14 | -$27.99M derived: sum of 4 quarters · filed 2025-11-12 |
| 2025-03-31 | -$8.19M 10-Q · filed 2025-05-15 | -$11.55M derived: sum of 2 quarters · filed 2025-05-15 | -$18.52M derived: sum of 3 quarters · filed 2025-11-12 | -$22.89M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-12-31 | -$3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$10.34M derived: sum of 2 quarters · filed 2025-11-12 | -$14.70M derived: sum of 3 quarters · filed 2025-11-12 | -$17.43M 10-K · filed 2025-03-31 |
| 2024-09-30 | -$6.97M 10-Q · filed 2025-11-12 | -$11.34M derived: sum of 2 quarters · filed 2025-11-12 | -$14.06M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$4.37M 10-Q · filed 2025-08-14 | -$7.10M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | -$2.73M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $17.91M 10-K · filed 2025-03-31 | |||
| 2020-12-31 | -$37.23M 10-K · filed 2021-03-31 | |||
| 2019-12-31 | -$28.30M 10-K · filed 2021-03-31 | |||
| 2018-12-31 | -$26.75M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |